Trisubstituted 1,3,5-Triazine Derivatives

A method of treating Human Immunodeficiency Virus infection comprising administering to a subject in need thereof an effective amount of a compound of formula ##STR16## a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein

• A is CH, CR.sup.4 or N;
• n is 0, 1, 2, 3 or 4;
• R.sup.1 and R.sup.2 are each independently selected from hydrogen, hydroxy, C.sub.1-12 alkyl, C.sub.1-12 alkyloxy, C.sub.1-12 alkylcarbonyl, C.sub.1-12 alkyloxycarbonyl, aryl, amino, mono- or di(C.sub.1-12 alkyl)amino, mono- or di(C.sub.1-12 alkyl)aminocarbonyl wherein each of the aforementioned C.sub.1-12 alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C.sub.1-6 alkyloxy, hydroxyC.sub.1-6 alkyloxy, carboxyl, C.sub.1-6 alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl, aminocarbonylamino, mono- or di(C.sub.1-6 alkyl)amino, aryl and Het;
• or
• R.sup.1 and R.sup.2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C.sub.1-12 alkyl)aminoC.sub.1-4 alkylidene;
• R.sup.3 is hydrogen, aryl, C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkyl, C.sub.1-6 alkyloxycarbonyl, C.sub.1-6 alkyl substituted with C.sub.1-6 alkyloxycarbonyl;
• and
• each R.sup.4 independently is hydroxy, halo, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy;
• L is --X--R.sup.5 or --X--Alk--R.sup.6 ;
• wherein
• R.sup.5 and R.sup.6 each independently are indanyl, indolyl or phenyl;
• each of said indanyl, indolyl or phenyl may be substituted with one, two, three, four or five substituents each independently selected from halo, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, hydroxy, C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkyloxycarbonyl, formyl, cyano, nitro, amino and trifluoromethyl;
• and
• X is --N H--NH--, --N.dbd.N--, --O--, --S--, --S(.dbd.O)-- or --S(.dbd.O).sub.2 --;
• aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, cyano, nitro and trifluoromethyl;
• Het is an aliphatic or aromatic heterocyclic radical;
• said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group;
• and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy.